ICT10336

ICT10336 is a hypoxia-responsive prodrug of ATR inhibitor, AZD6738 (HY-19323) . ICT10336 is hypoxia-activated and specifically releases AZD6738 only in hypoxic conditions in vitro. This can inhibit ATR activation (T1989 and S428 phosphorylation) and subsequently abrogate HIF1a-mediated adaptation of hypoxic cancers cells, thus selectively inducing cell death in 2D and 3D cancer models. ICT10336 is a metabolic substrate of CYPOR activity.

Product Specifications

UNSPSC

12352005

Target

ATM/ATR

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ict10336.html

Smiles

C[C@H](COCC1)N1C2=CC(C3(S(=NC([C@H](CC(C)C)NC(OCC4=CN=C([N+]([O-])=O)N4C)=O)=O)(C)=O)CC3)=NC(C5=C6C(NC=C6)=NC=C5)=N2

Molecular Formula

C32H40N10O7S

Molecular Weight

708.79

References & Citations

[1]Francis M Barnieh, et al. Hypoxia-Responsive Prodrug of ATR Inhibitor, AZD6738, Selectively Eradicates Treatment-Resistant Cancer Cells. Adv Sci (Weinh) . 2024 Jul 8:e2403831.